What has changed in the last 20 years of HER2-targeting, and what’s on the horizon? Wonderful discussions with amazing experts & friends Javier Cortes MD PhD Erika Hamilton, MD #ShanuModi during today’s symposium. Thanks Medscape for having us!

Happy October 25th. The Song of the Cell launches today with a talk in Boston. Talk dates and a short erratum (caught prepub) on my new website siddharthamukherjee.com

Me at poster sessions

Our CMO Anu Antony MD MPH MBA attended #ESMO2022 last month & wanted to share her takeaways in our blog, featuring #ADCs from Aditya Bardia, MD, #HER2low #breastcancer from Paolo Tarantino. & Dr. Shanu Modi, & #cancer #immunotherapy from Sherene Loi, MD MD & Marleen Kok MD.
simbiosys.com/takeaways-from…

Sara Tolaney, MD, MPH discusses sacituzumab govitecan in HR+/ HER2– metastatic breast cancer with Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD. #bcsm | Sara Tolaney Martin Dietrich, MD, PhD Gregory Vidal

ow.ly/s0GA50Lh4sr

Join us this week (Oct 26-29) for the 2nd MedscapeLIVE Perspectives in Breast Cancer Care Conference, where an outstanding faculty will review current standards & recent advancements in breast oncology!Agenda and registration here: na.eventscloud.com/website/35276/… #PBCClive22 #bcsm

Everybody knows that Vincent van Gogh loved the colour yellow. But why?

Well, the story begins 19,000 years ago...

ATP Napoli Cup ☀️

Four years ago today: my fist ESMO Congress!

View our top 5 articles of the week featuring: Paolo Tarantino Aparna Raj Parikh Laurence Albiges Ben Fangman, MD Scott Kopetz Ibrahim Halil SAHIN, MD

1. ow.ly/CICC50Lh4cT

2. ow.ly/syKa50Lh4cU

3. ow.ly/5SnG50Lh4cV

4. ow.ly/qM5r50Lh4cR

5. ow.ly/N3U650Lh4cS

48h to the MedscapeLIVE symposium on the Unfinished Revolution in HER2-targeting. Join us!
na.eventscloud.com/website/48323/

Internship was particularly tough for me especially being in a new country & a very demanding schedule/stress. I contemplated quitting medicine altogether that year. Just because we suffered does not mean subsequent generations have to continue to suffer. Things should change..

Did you know that the immunotherapy monoclonals (pembro, nivo) maintain their effectiveness at a fraction of the FDA-approved dose?

Huge potential for cost-savings here.
See my and Daniel Goldstein MD's commentary in Journal of Clinical Oncology today
👇🏼👇🏼👇🏼
ascopubs.org/doi/abs/10.120…
1/

🚨Now online at European Journal of Cancer
👉Health-related quality of life analysis from the ASCENT trial
#SybilleLoibl Sara Tolaney #MartinePiccart Mafalda Oliveira Hope Rugo Aditya Bardia, MD Javier Cortes MD PhD
OncoAlert #bcsm #TNBC #HRQoL #SacituzumabGovitecan
sciencedirect.com/science/articl…